Gufic Biosciences Adds $50,000 to Selvax Biotech Investment

Gufic Biosciences Ltd announced on April 28, 2026, an additional investment of USD 50,000 in Selvax Pty Ltd., an Australian biotechnology company. The company acquired 3,78,350 ordinary shares at AUD 0.20 each, increasing its stake in Selvax. Selvax is developing an immunology-based treatment for large solid tumours.

This latest tranche aims to secure access to Selvax's proprietary technology and explore potential commercial opportunities in the oncology space. Gufic's previous investment in Selvax was disclosed on February 13, 2026.

Strategic Importance

This investment signifies Gufic Biosciences' strategic intent to diversify beyond its traditional pharmaceutical offerings into the innovative field of biotechnology. By investing in Selvax, Gufic seeks to tap into novel research for oncology treatments, positioning itself for future growth and market differentiation. The move into immunology-based therapies aligns with global trends in cancer treatment and could open significant commercial avenues, potentially in both human and veterinary medicine.

Background and Strategy

Gufic Biosciences Ltd, an established Indian pharmaceutical player, has been signaling a shift towards innovation and diversification. The company's traditional focus includes Active Pharmaceutical Ingredients (APIs), formulations, and sterile injectables. This latest investment follows a prior disclosure on February 13, 2026, indicating an ongoing commitment to Selvax Pty Ltd. Management has expressed a desire to explore new healthcare and biotechnology avenues to build long-term value.

Development Risks

The primary risk for this investment lies in the successful development and commercialization of Selvax's novel cancer therapy. This is inherently a long-term and high-risk endeavor within the biotech sector, with clinical and regulatory hurdles ahead.

Industry Context

Several Indian pharmaceutical companies are actively expanding into biotechnology and research-intensive areas. Giants like Biocon Ltd, Sun Pharmaceutical Industries Ltd, and Dr. Reddy's Laboratories Ltd are investing heavily in biologics and novel drug discovery. These peers are enhancing their R&D capabilities and exploring global markets for advanced therapies, similar to Gufic's strategic direction.

Selvax Financials Snapshot

• Selvax Pty Ltd had a total issued share capital of AUD 52,85,176 as of June 30, 2025.
• For the financial year ended June 30, 2025, Selvax reported a total income of AUD 356,972.

Looking Ahead

Investors will be tracking Selvax's progress in clinical trials and regulatory approvals for its cancer therapy. Further monitoring will include potential future funding rounds by Gufic Biosciences, how Selvax's technology is integrated within Gufic's broader strategy, and changes in the value of Gufic's shareholding.